Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Thermo Fisher Scientific has been based in the town since 1970 and is planning to expand over the next few years ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

U.S. Health Secretary Robert F. Kennedy Jr’s newly appointed Advisory Committee on Immunization Practices (ACIP) upheld ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...